Lisa Walter
Stock Analyst at RBC Capital
(2.97)
# 1,569
Out of 5,090 analysts
11
Total ratings
77.78%
Success rate
23.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $8.58 | +86.48% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $11.21 | +185.46% | 2 | Nov 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $41 → $45 | $32.49 | +38.53% | 2 | Nov 6, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $28 → $39 | $16.75 | +132.82% | 2 | Nov 6, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $569 → $587 | $485.21 | +20.98% | 2 | Oct 30, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $3 → $4 | $4.18 | -4.19% | 1 | Oct 28, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $17 → $19 | $22.05 | -13.81% | 1 | Aug 1, 2025 |
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $8.58
Upside: +86.48%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $11.21
Upside: +185.46%
Viridian Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $41 → $45
Current: $32.49
Upside: +38.53%
EyePoint Pharmaceuticals
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $16.75
Upside: +132.82%
United Therapeutics
Oct 30, 2025
Maintains: Outperform
Price Target: $569 → $587
Current: $485.21
Upside: +20.98%
Adverum Biotechnologies
Oct 28, 2025
Maintains: Sector Perform
Price Target: $3 → $4
Current: $4.18
Upside: -4.19%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Sector Perform
Price Target: $17 → $19
Current: $22.05
Upside: -13.81%